Dabrafenib – LuciDabra

What it treats:

Dabrafenib is a targeted cancer therapy used primarily as a BRAF inhibitor to treat cancers with specific BRAF gene mutations.

Melanoma

Dabrafenib is approved for adults with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, as detected by an gene test. It is often used in combination with trametinib (a MEK inhibitor) to enhance efficacy, but can also be used as a single agent.

Non-Small Cell Lung Cancer (NSCLC)

In combination with trametinib, dabrafenib is approved for adults with metastatic NSCLC harboring BRAF V600E mutations, as confirmed by genetic testing.

Anaplastic Thyroid Cancer (ATC)

Dabrafenib, in combination with trametinib, is approved for adults with locally advanced or metastatic ATC with BRAF V600E mutations when no satisfactory locoregional treatment options are available.

Solid Tumors

In combination with trametinib, dabrafenib is approved for adults and pediatric patients (aged 1 and older) with unresectable or metastatic solid tumors with BRAF V600E mutations

Low-Grade Glioma (LGG)

In combination with trametinib, dabrafenib is approved for pediatric patients (aged 1 and older) with low-grade gliomas with a BRAF V600E mutation who require systemic therapy.